プレシジョンメディシンの市場規模、シェア、動向分析レポート：用途別、最終用途別、地域別、セグメント予測、2024年～2030年

プレシジョンメディシン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のプレシジョンメディシン市場規模は2030年までに2,492億4,000万米ドルに達し、2024年から2030年までのCAGRは16.3％で成長すると予測されています。

費用対効果の高いゲノム・分子生物学的検査法のイントロダクション、がんや希少疾患の有病率の増加、プレシジョンメディシンにおけるビッグデータ利用の高まりといった動向は、市場成長を後押しする主要因の一部です。

ヒトゲノムプロジェクトは、全ゲノム配列決定や標的配列決定などの素晴らしい最先端技術を導入しました。これらの技術は、ゲノムの研究や、様々な病気の治療のための個別化治療の作成のために研究者によって使用されています。今日、腫瘍学、免疫学、神経学などの分野における疾患の流行は、世界中で急速に増加しています。

研究者、ヘルスケア専門家、そして大手製薬会社やバイオテクノロジー会社は、患者の健康のために新たな治療法の選択肢を見出すために協力しています。現在、さまざまな種類のがんを治療するために、多くの治療法や薬剤が臨床試験中です。さらに、研究者たちは、がん以外の疾患領域における精密医薬品や診断法の開発にも関心を示しています。

治療とは別に、診断分野もここ数年で急成長を遂げています。次世代シーケンシング（NGS）、バイオマーカー、コンパニオン診断、難解な検査の使用は、医薬品の処方パターンを変え、影響を与える可能性があります。個別化された医薬品は、今後20年以内に大成功を収める可能性が非常に高く、以前は不可能だった少数の難病の治療や治癒を可能にする能力を持っています。

この分野の成長には、政府や規制機関の関与が非常に重要な役割を果たしています。2015年、当時の米国政府はプレシジョン・メディシン・イニシアティブの立ち上げを発表しました。翌年、中国は「中国プレシジョンメディシンイニシアティブ」を立ち上げました。これは15年計画で、同国を精密治療開発のリーダー国にすることを目指すものです。

現在、バイオテクノロジー企業や製薬企業の改善パイプラインにある医薬品の40％以上がバイオマーカーを組み込んでいます。同概要では、過去5年間にいくつかのバイオ製薬企業が共同事業やジョイントベンチャーを行っており、今後数年間も継続する見込みであることも推奨しています。このように、診断・治療プレシジョンメディシン市場は計り知れない可能性を秘めており、急速に患者ケアの基本分野へと変貌しつつあります。

プレシジョンメディシン市場レポートハイライト

• 2023年は治療薬分野が市場をリードし、予測期間のCAGRは15.8%で成長すると予測されます。
• 病院分野は2023年の売上高シェア60.0%で市場をリード。病院は、その包括的なインフラと多様な患者集団へのアクセスにより、個別化医療に理想的な環境を提供します。
• 北米のプレシジョンメディシン市場は2023年に53.62%のシェアを占めました。2022年に発表されたPMCのレポートによると、2014年以降FDAによって承認された医薬品の4つに1つ以上が個別化医療で占められています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 プレシジョンメディシン市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 市場機会分析
• プレシジョンメディシン市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • 数量分析（機器）

第4章 プレシジョンメディシン市場：用途の推定・動向分析

• 世界のプレシジョンメディシン市場：用途ダッシュボード
• 世界のプレシジョンメディシン市場：用途変動分析
• 世界のプレシジョンメディシン市場：用途別、収益別
• 診断
• 治療

第5章 プレシジョンメディシン市場：最終用途の推定・動向分析

• 世界のプレシジョンメディシン市場：最終用途ダッシュボード
• 世界のプレシジョンメディシン市場：最終用途変動分析
• 世界のプレシジョンメディシン市場：最終用途別、収益別
• 在宅ケア
• 病院
• 臨床検査室
• その他

第6章 プレシジョンメディシン市場：カテゴリー、用途、最終用途、調査手法別地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Janssen Global Services, LLC
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • 23andMe, Inc.
  • NeoDiagnostix
  • Myriad Genetics
  • Medtronic
  • GE Healthcare
  • Abbott
  • QIAGEN

List of Tables

• Table 1 List of abbreviation
• Table 2 North America precision medicine market, by region, 2018 - 2030 (USD Million)
• Table 3 North America precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 4 North America precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 5 U.S. precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 6 U.S. precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 7 Canada precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 8 Canada precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 9 Mexico precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 10 Mexico precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 11 Europe precision medicine market, by region, 2018 - 2030 (USD Million)
• Table 12 Europe precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 13 Europe precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 14 Germany precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 15 Germany precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 16 UK precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 17 UK precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 18 France precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 19 France precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 20 Italy precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 21 Italy precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 22 Spain precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 23 Spain precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 24 Denmark precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 25 Denmark precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 26 Sweden precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 27 Sweden precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 28 Norway precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 29 Norway precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific precision medicine market, by region, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 33 China precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 34 China precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 35 Japan precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 36 Japan precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 37 India precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 38 India precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 39 South Korea precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 40 South Korea precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 41 Australia precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 42 Australia precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 43 Thailand precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 44 Thailand precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 45 Latin America precision medicine market, by region, 2018 - 2030 (USD Million)
• Table 46 Latin America precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 47 Latin America precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 48 Brazil precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 49 Brazil precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 50 Argentina precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 51 Argentina precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 52 MEA precision medicine market, by region, 2018 - 2030 (USD Million)
• Table 53 MEA precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 54 MEA precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 55 South Africa precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 56 South Africa precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 57 Saudi Arabia precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 59 UAE precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 60 UAE precision medicine market, by end-use, 2018 - 2030 (USD Million)
• Table 61 Kuwait precision medicine market, by application, 2018 - 2030 (USD Million)
• Table 62 Kuwait precision medicine market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in Asia Pacific
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Precision medicine market: market outlook
• Fig. 14 Precision medicine competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Precision medicine market driver impact
• Fig. 18 Precision medicine market restraint impact
• Fig. 19 Precision medicine market: Application movement analysis
• Fig. 20 Precision medicine market: Application outlook and key takeaways
• Fig. 21 Diagnostics estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Genetic tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Direct to Consumer Tests estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Esoteric Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Oncology estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Respiratory Diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Skin Diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 CNS Disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Immunology estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Genetic Diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Medical Devices market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Precision medicine market: End-use movement analysis
• Fig. 38 Precision medicine market: End-use outlook and key takeaways
• Fig. 39 Home care market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Hospitals estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Clinical laboratories market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Global precision medicine market: Regional movement analysis
• Fig. 44 Global precision medicine market: Regional outlook and key takeaways
• Fig. 45 Global precision medicine market share and leading players
• Fig. 46 North America, by country
• Fig. 47 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 U.S. key country dynamics
• Fig. 49 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Canada key country dynamics
• Fig. 51 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Mexico key country dynamics
• Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 UK key country dynamics
• Fig. 56 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Germany key country dynamics
• Fig. 58 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 France key country dynamics
• Fig. 60 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Italy key country dynamics
• Fig. 62 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Spain key country dynamics
• Fig. 64 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Denmark key country dynamics
• Fig. 66 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Sweden key country dynamics
• Fig. 68 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Norway key country dynamics
• Fig. 70 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 China key country dynamics
• Fig. 73 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Japan key country dynamics
• Fig. 75 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 India key country dynamics
• Fig. 77 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Thailand key country dynamics
• Fig. 79 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 South Korea key country dynamics
• Fig. 81 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Australia key country dynamics
• Fig. 83 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Brazil key country dynamics
• Fig. 86 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Argentina key country dynamics
• Fig. 88 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 South Africa key country dynamics
• Fig. 91 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Saudi Arabia key country dynamics
• Fig. 93 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 UAE key country dynamics
• Fig. 95 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Kuwait key country dynamics
• Fig. 97 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Market share of key market players- Precision medicine market

Precision Medicine Market Growth & Trends:

The global precision medicine market size is expected to reach USD 249.24 billion by 2030 growing at a CAGR of 16.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Trends such as introduction of cost-effective genomic and molecular biology testing methods, increasing prevalence of cancer and rare diseases, and rising use of big data in precision medicine are some of the key factors boosting market growth.

The Human Genome Project introduced some marvelous cutting-edge techniques such as whole genome sequencing and targeted sequencing. These technologies are being used by researchers for the study of genomes and creation of personalized therapies for treatment of various illnesses. Today, the prevalence of diseases in areas such as oncology, immunology, and neurology has rapidly increased across the globe.

Researchers, healthcare professionals, and big pharma and biotech companies are working together to recognize new focused treatments options for the wellbeing of patients. Currently, there are many therapies and drugs under clinical trials for treatment of different types of cancers. Moreover, researchers have also shown an inclination toward development of precision medicines and diagnostics in non-oncologic disease areas.

Apart from therapeutics, the diagnostics field has also witnessed rapid growth in the past few years. The use of next generation sequencing (NGS), biomarkers, companion diagnostics, and esoteric tests can possibly change and affect prescription patterns of pharmaceutical medicines. Personalized medicines have very high chances of becoming a massive success in the next 20 years and have the capacity to treat and cure a few obstinate illnesses, which was not possible before.

Involvement of government and regulatory bodies has played a very important role in the growth of this field. In 2015, the then U.S. government announced the launch of the Precision Medicine Initiative. The following year, China launched the China Precision Medicine Initiative, which is a 15-year project that aims to build the country as a leader in development of precision therapies.

At present, more than 40% of the medications in biotech and pharmaceutical companies' improvement pipeline incorporate biomarkers. The overview likewise recommended that some biopharmaceutical organizations have collaborated and joint their ventures in the past five years and are expected to continue doing so in the coming years. The diagnostic and therapeutic precision medicine market thus holds immense potential and is quickly turning into a fundamental segment of patient care.

Precision Medicine Market Report Highlights:

• The therapeutics segment led the market in 2023 and is expected to grow at a CAGR of 15.8% over the forecast period.
• The hospitals segment led the market with a revenue share of 60.0% in 2023. Hospitals provide the ideal setting for personalized medicine due to their comprehensive infrastructure and access to diverse patient populations.
• The North America precision medicine market accounted for 53.62% share in 2023. PMC report published in 2022 notes that personalized medicines now account for more than one in four drugs approved by the FDA since 2014.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End-use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application and End-use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Precision Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in next-generation sequencing
    • 3.2.1.2. Expanding portfolio of companion/associated diagnostics
    • 3.2.1.3. Increasing prevalence of cancer & usage of biomarkers for precision medicine cancer therapy
    • 3.2.1.4. Growing healthcare expenditure triggering development of effective precision medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Presence of nonvalue-based precision medicine diagnostics reimbursement policy
    • 3.2.2.2. Lack of proper intellectual property regulations for precision medical technologies
    • 3.2.2.3. Nonstructural development of biomarkers
• 3.3. Market opportunity analysis
  • 3.3.1.1. Advancements in genomic technologies
• 3.4. Precision Medicine Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape
  • 3.4.3. Pricing Analysis
  • 3.4.4. Volume Analysis (Instruments)

Chapter 4. Precision Medicine Market: Application Estimates & Trend Analysis

• 4.1. Global Precision Medicine Market: Application Dashboard
• 4.2. Global Precision Medicine Market: Application Movement Analysis
• 4.3. Global Precision Medicine Market by Application, Revenue
• 4.4. Diagnostics
  • 4.4.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Genetic Testing
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Direct to Consumer Tests
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Esoteric Tests
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Therapeutics
  • 4.5.1. Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Pharmaceuticals
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.2. Oncology
    • 4.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.3. Respiratory Disease
    • 4.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.4. Skin Diseases
    • 4.5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.5. CNS Disorders
    • 4.5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.6. Immunology
    • 4.5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.7. Genetic Diseases
    • 4.5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.8. Others
    • 4.5.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Medical Devices
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Precision Medicine Market: End-use Estimates & Trend Analysis

• 5.1. Global Precision Medicine Market: End-use Dashboard
• 5.2. Global Precision Medicine Market: End-use Movement Analysis
• 5.3. Global Precision Medicine Market by End-use, Revenue
• 5.4. Home care
  • 5.4.1. Home care market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hospitals
  • 5.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Clinical Laboratories
  • 5.6.1. Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Precision Medicine Market: Regional Estimates & Trend Analysis by Category, Application, End-use and Methodology

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. F. Hoffmann-La Roche Ltd
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Siemens Healthineers AG
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Janssen Global Services, LLC
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Illumina, Inc.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Quest Diagnostics Incorporated
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. 23andMe, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. NeoDiagnostix
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Myriad Genetics
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Medtronic
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. GE Healthcare
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Abbott
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. QIAGEN
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives